trending Market Intelligence /marketintelligence/en/news-insights/trending/ls_8kk-dasqihjhuys70ia2 content esgSubNav
In This List

Karyopharm, Antengene sign license deal for China, parts of Asia

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Karyopharm, Antengene sign license deal for China, parts of Asia

Karyopharm Therapeutics Inc. and Shanghai-based Antengene Corp. signed a deal to develop and commercialize four Karyopharm drugs in China and certain regions in Asia.

The licensing deal covers Karyopharm oral drug candidates including selinexor, eltanexor, verdinexor and KPT-9274.

Under the terms of the agreement, Karyopharm will receive $12 million up front and can receive up to an additional $150 million if Antengene meets certain future development, regulatory and commercial milestones.

Newton, Mass-based Karyopharm is also eligible to receive royalties from future net sales of selinexor and eltanexor in China and Macau, and verdinexor and KPT-9274 in the relevant territories.

Antengene will receive exclusive rights to the compounds in the agreed to territories, and shoulder development, manufacturing and commercialization costs.

The Chinese pharmaceutical company will gain rights to selinexor and eltanexor for all human cancer indications in China and Macau; KPT-9274 in all human cancers; and verdinexor in human non-oncology indications in mainland China, Macau, Taiwan, Hong Kong, South Korea, and countries in the Association of Southeast Asian Nations.

Further, Antengene may participate in global clinical studies of the four therapies, bearing the cost for patients enrolled studies in the agreed to territories.

The deal will allow Karyopharm to focus internal resources on executing late-phase selinexor trials and pursue regulatory approval in the U.S. and E.U., said Karyopharm CEO Michael Kauffman.